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Abstract
Background:  Awareness of the potential impact of malaria among school-age children has stimulated
investigation into malaria interventions that can be delivered through schools. However, little evidence is available
on the costs and cost-effectiveness of intervention options. This paper evaluates the costs and cost-effectiveness
of intermittent preventive treatment (IPT) as delivered by teachers in schools in western Kenya.
Methods: Information on actual drug and non-drug associated costs were collected from expenditure and salary
records, government budgets and interviews with key district and national officials. Effectiveness data were
derived from a cluster-randomised-controlled trial of IPT where a single dose of sulphadoxine-pyrimethamine and
three daily doses of amodiaquine were provided three times in year (once termly). Both financial and economic
costs were estimated from a provider perspective, and effectiveness was estimated in terms of anaemia cases
averted. A sensitivity analysis was conducted to assess the impact of key assumptions on estimated cost-
effectiveness.
Results: The delivery of IPT by teachers was estimated to cost US$ 1.88 per child treated per year, with drug
and teacher training costs constituting the largest cost components. Set-up costs accounted for 13.2% of overall
costs (equivalent to US$ 0.25 per child) whilst recurrent costs accounted for 86.8% (US$ 1.63 per child per year).
The estimated cost per anaemia case averted was US$ 29.84 and the cost per case of Plasmodium falciparum
parasitaemia averted was US$ 5.36, respectively. The cost per case of anaemia averted ranged between US$ 24.60
and 40.32 when the prices of antimalarial drugs and delivery costs were varied. Cost-effectiveness was most
influenced by effectiveness of IPT and the background prevalence of anaemia. In settings where 30% and 50% of
schoolchildren were anaemic, cost-effectiveness ratios were US$ 12.53 and 7.52, respectively.
Conclusion: This study provides the first evidence that IPT administered by teachers is a cost-effective school-
based malaria intervention and merits investigation in other settings.
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Introduction
In Africa, there is increasing evidence of the dramatic
reductions in malaria mortality and morbidity in early
childhood due to recent up-scaling of malaria control
efforts [1-4]. There is however some concern that these
gains in early childhood may, as a consequence of
decreased transmission and a slower acquisition of expo-
sure-dependent immunity, lead to an increased incidence
of malaria among older children [5]. Coincidental with
this changing epidemiology of malaria, there has been
increased recognition of the consequences of malaria in
children of school-age, including detrimental effects on
haemoglobin levels [6,7] and learning and educational
achievement [8,9]. Consequently, there has been a
renewed interest in the control of malaria in older chil-
dren who attend school [10-12]. However, there is cur-
rently little international consensus as to the optimal
intervention approach. There is also a lack of evidence on
the costs and cost-effectiveness of available options for
school-based malaria control.
An initial crude cost analysis of options for malaria con-
trol in Kenyan schools in 2000 concluded that chemo-
prophylaxis using the then recommended drug
(Proguanil) delivered through schools would be prohibi-
tively expensive [11]. Instead it was suggested that the pro-
motion of prompt and effective diagnosis and treatment
in schools would represent an affordable approach to
address malaria in schools. However, the practicality and
effectiveness of such an approach has only been explored
in pilot projects [13-15], and there remain a number of
operational challenges in the provision of treatment in
schools, including the reliability of diagnosis by non-
health personnel, the long term motivation of teachers to
play a health role, and challenges associated with the
recent introduction of artemisinin combination therapies.
An alternative school-based strategy, already proven effec-
tive for protecting pregnant women and infants from
malaria-related morbidity, is intermittent preventive treat-
ment (IPT). A recent proof-of-principle trial in western
Kenya showed that mass administration of a full thera-
peutic course of anti-malarial drugs to schoolchildren
once a term, irrespective of infection status, dramatically
reduced malaria parasitaemia, almost halved the rates of
anaemia, and significantly improved cognitive ability
[16]. In light of these promising results, it is important to
replicate the results in other epidemiological settings. It is
also clearly important to obtain information on the oper-
ational costs and cost-effectiveness of a delivery model for
school-based IPT which can be implemented as part of an
integrated school health programme. School health pro-
grammes already provide school children with deworm-
ing and micronutrients [17] and offer major cost
advantages because of the use of the existing school infra-
structure and the fact that the target population represents
an accessible and relatively stable group. Evidence from
existing programmes indicates that school-based delivery
of anthelmintics is extremely cost-effective [18].
This paper aims to estimate the costs and cost-effective-
ness of IPT delivered by teachers in Bondo District of
Nyanza Province, western Kenya. Economic costs are cal-
culated in order to help inform resource allocation and
allow for comparison with alternative school-based inter-
vention and across various health interventions, whereas
financial costs are provided to inform replication of the
approach. The analysis also explores how costs vary with
the drug price and organization of delivery of the inter-
vention as well as with differences in intervention effec-
tiveness and background prevalence of anaemia.
Methods
Description of the IPT trial
A cluster-randomised, double-blind, placebo-controlled
trial was conducted in 30 schools (15 intervention and 15
control schools) in Bondo District, western Kenya, where
malaria transmission is stable and perennial [19]. The
study design and results have been detailed elsewhere
[16]. The main objective of the trial was to determine the
efficacy of IPT given at four-monthly intervals (once a
school term) against anaemia (defined as haemo-
globin<110 g/L). The trial also evaluated the impact of
intervention on the prevalence and intensity of Plasmo-
dium falciparum infection, mean haemoglobin, sustained
attention and educational achievement. Children, aged
5–18 years, received one dose of sulphadoxine-pyrimeth-
amine (SP) and three daily doses of amodiaquine (AQ),
on three occasions within a 12-month period (IPT was
given once each school term). IPT was first given in May
2005, coinciding with a seasonal peak in transmission,
and then repeated in September 2005 and January 2006.
During the trial, treatment was provided by the research
team during scheduled visits to schools, in close collabo-
ration with district teams from the Ministry of Health
(MoH) and Ministry of Education (MoE). Mass treatment
with albendazole for soil-transmitted helminth infections
was also provided to children in all 30 schools. Cross-sec-
tional parasitological and haematological surveys were
conducted in all schools in February 2005 and in March
2006, at the end of the intervention period.
Implementation of teacher administrated programme of 
IPT
The present study estimates the costs of a school-based
delivery of IPT in Bondo District, covering a school popu-
lation in 2006 of approximately 74,000 school children.
IPT comprises a single dose of SP on the first day and AQ
as a daily dose over the course of three days. In order to
reflect programmatic implementation it is assumed thatMalaria Journal 2008, 7:196 http://www.malariajournal.com/content/7/1/196
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IPT is delivered by teachers in schools, with supervision
provided by staff of the District Health Office (DHO) at
local levels and of the Division of Malaria Control
(DoMC), MoH at a national level. Justification of such a
delivery model is that it represents a well established
delivery model of anthelmintics and micronutrients as
part of school health programmes. Furthermore, previous
studies demonstrate the ability of teachers to provide pre-
sumptive treatment for clinical malaria to schoolchildren
in schools [13-15].
Cost analysis
Cost data were collected from expenditure and salary
records (budgetary records where expenditure data were
not available) and from interviewing key district and
national officials. Data collection was based on an item-
ized menu approach [20] and was undertaken between
June–August 2006, shortly after the conclusion of the
trial. Results are presented from a provider (national con-
trol programme) perspective, including those costs
incurred by the MoE. Costs to households were excluded
since costs of accessing treatment in their own schools
were considered negligible. Both financial and economic
costs were estimated. Financial costs represent monies
paid for the implementation of the intervention by the
programme at national and local levels. Economic costs
include the opportunity cost of using existing government
staff (including teachers) to implement the programme
and these costs were estimated from government pay
scales. Research costs were not included, but care was
taken to include costs associated with programme moni-
toring. All costs were converted from Kenyan shillings to
US dollars using the average exchange rate in 2006: 67.8
Kenyan Shillings = US$ 1 http://www.oanda.com/con
vert/classic. Capital costs with a lifespan longer than 12
months were annuitized using a discount rate of 5% fol-
lowing standard practice [20].
Programme implementation costs were differentiated
between initial set-up and recurrent costs, and separated
into the following categories: 1) drug procurement; 2)
drug distribution; 3) national supervision; 4) local super-
vision; 5) training; and 6) drug administration. Office
equipment, training of trainers and community sensitiza-
tion were the main set-up costs. The need for annual
refresher training of teachers was assumed given high rates
of staff turnover in schools, and included as a recurrent
cost. Unit costs are provided in the supplementary infor-
mation [Additional file 1].
Wholesale drug prices for preferred MoH brands were
used. Drugs were stored at the district hospital, with rele-
vant storage costs estimated. Ten percent drug wastage was
assumed to account for expiration and loss of drugs. On
the basis of discussions with local officials it was decided
to model delivery costs on the basis of the distribution
system used by the MoE to distribute anthelmintic tablets
for deworming to schools. Subsequently, transport, per-
sonnel and supervision costs were estimated assuming
that one vehicle can distribute drugs to ten schools per
working day, with relevant costs for storage in the district
included.
Programme supervision at the national level was esti-
mated by assuming that a focal person at the DoMC
would spend 10% of their time overseeing the programe,
with relevant office costs included. These national super-
vision costs were estimated by modelling a national IPT
programme in the 27 highly malaria endemic districts of
Kenya and apportioning relevant costs to Bondo district.
Local supervision of treatment was assumed to be logisti-
cally similar to supervision of school-based deworming,
where health centre staff supervise treatment and deal
with any side-effects arising, and costs were calculated
accordingly.
Training was assumed to involve two components: first,
the training of trainers and district officials (including 22
trainers and lasting three days); second, the training of
teachers (two teachers from each school and lasting one
day). Training of trainers is assumed at the beginning of
the programme and thus represents set-up costs, whereas
training of teachers is considered a recurrent cost. Training
aimed to enhance awareness of malaria in schoolchildren
and provide specific skills that would enable non-health
staff to deliver IPT in schools. Health personnel were
briefed on how to provide supervision and support to
teachers. Training costs were based on previous experience
in implementing school-based deworming and included
opportunity costs of staff time valued at full salary costs
(including tax and allowances), and costs related to trans-
port, venue hire and supplies. Costs of community sensi-
tization were estimated based on the time of two teachers
per school taken to hold two parent teacher association
meetings in schools (three hours per meeting) and
included in the recurrent costs.
Administration of IPT included several activities with
associated costs: photocopying of treatment instructions
and report forms; teacher time spent on preparation, treat-
ment and reporting. Retrospective estimates of time taken
to deliver IPT during the efficacy trial were obtained
through interviews with teachers in the intervention
schools and used to calculate the opportunity cost of the
time it would take teachers to administer IPT. It is
assumed no payment would be made to teachers to
deliver treatment. Additional supplies used during drug
administration included treatment registers and glucose
(to be co-administered with the bitter-tasting drugs to
minimize non-compliance with treatment).Malaria Journal 2008, 7:196 http://www.malariajournal.com/content/7/1/196
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Estimation of cost-effectiveness
Effectiveness was assessed in terms of cases of (i) anaemia
averted and (ii) P. falciparum parasitaemia averted, and
was derived from unadjusted results of the intervention
trial, calculated on the basis of intention-to-treat [16].
Both costs and effects were estimated for the intervention
compared to the counter-factual of "do-nothing". Out-
come measures were cost per child treated per year, the
cost per anaemia case averted and cost per case P. falci-
parum parasitaemia averted.
Sensitivity analysis
A one-way sensitivity analysis was performed around both
the main assumptions concerning costs and effectiveness.
Specifically, as the price of different antimalarial drugs
varies substantially and may also change over time and in
different settings, drug prices were varied to 50% and
200% of current drug prices. Drug wastage was varied
from 0% and 20%. An increase in personnel costs of 20%
was also investigated. Finally, the discount rate (base case
5%) was varied to 3 and 7% and the exchange rate was
varied to the highest and lowest levels reported for 2006
(1 US$ = Kenyan Shillings 74.5, 67.1).
As well as varying costs, differences in the effectiveness of
IPT and the background level of anaemia were explored in
the sensitivity analysis in order to explore potential cost-
effectiveness under operational conditions and in differ-
ent epidemiological settings. Specifically, the effectiveness
of IPT in reducing anaemia was changed from 50% to
30% and 10%. The effectiveness in reducing malaria par-
asitaemia was changed from 88% to 60% and 40%.
Finally, background prevalence of anaemia was varied
from 12.6% to 30% and 50%.
For the purpose of estimating costs of IPT using alternative
drug regimes, the choice of drugs was changed to include
two relevant alternatives: 1) SP alone and 2) Dihydroar-
temisinin-Piperaquine (DP) – two drug regimes currently
being investigated in a treatment efficacy trial against
asymptomatic parasitaemic among schoolchildren in
Uganda. In the Bondo intervention trial, IPT was given
three times a year to correspond with the three school
terms [16]; however because this could be reduced to
twice a year by delivering IPT during the two main malaria
seasons, the costs of biannual IPT delivery was also mod-
elled. Note that only cost implications were assessed;
effectiveness of alternative drug regimes remains
unknown at present.
Ethical clearance
Ethical clearance for the cost analysis, as well as the IPT
trial, was given by the ethical committees of Kenyatta
National Hospital, Kenya and London School of Hygiene
& Tropical Medicine.
Results
Programme costs
In Bondo district, there were in 2006 approximately
74,000 schoolchildren attending 62 schools. The overall
financial cost (i.e. market-value transaction costs) of a
school-based, teacher administered IPT programme to all
schools in the district was estimated to be US$ 88,859.
The overall economic cost (i.e. financial plus opportunity
costs of teachers and government officials' time) was esti-
mated to be US$ 139,120. Table 1 presents the economic
costs of the programme by major cost components. Set-up
costs, namely equipment and initial training of trainers,
accounted for 13.2% of overall costs whilst recurrent costs
account for 86.8%. The estimated economic cost per child
treated per year in Bondo district was US$ 1.88. The finan-
cial cost was US$ 1.20 per child treated per year. The set-
up cost was estimated to be US$ 0.25 per child, and the
annual recurrent cost US$ 1.63 per child treated per year.
The largest cost component was the purchase of SP and
AQ, which contributed to 38.4% of overall costs. In terms
Table 1: Annual economic cost of school-based IPT by major 
cost components (see additional file for breakdown of costs)
Major cost components Annual Cost (US$) % of total
SET-UP COSTS
Equipment 3,543 2.6
Salaries (opportunity costs) 5,019 3.6
Per diems 5,275 3.8
Stationary 425 0.3
Fuel 133 0.1
Insurance/maintenance 25 0.0
Accommodation and food 3,846 2.8
Total set-up costs 18,266 13.2
RECURRENT COSTS
Drugs 53,298 38.4
Stationary 2,498 1.8
Other consumables 2,044 1.5
Total consumables 57,840 41.7
Salaries (opportunity costs) 40,763 29.4
Incentives 1,217 0.9
Per diems 3,526 2.5
Total Personnel 45,506 32.8
Fuel 4,324 3.1
Insurance/maintenance 1,056 0.8
Local travel reimbursement 6,360 4.6
Total Transport 11,740 8.5
Accommodation and food 5,363 3.9
Other 124 0.1
Total recurrent costs 120,573 86.8
Total 138,839 100Malaria Journal 2008, 7:196 http://www.malariajournal.com/content/7/1/196
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of main activities, training of district staff and teachers was
the most expensive activity (22.3%), followed by drug
delivery costs (20.6%), transportation costs (10%) and
local supervision costs (6.4%). The costs of community
sensitization were minimal (2.3%) and the costs of
national supervision were negligible (<0.01%).
Effectiveness and cost effectiveness
In the unadjusted statistical analysis of data from the effi-
cacy trial, delivery of IPT was associated with a 50% reduc-
tion in the proportion of children that are anaemic [16].
IPT was also estimated to reduce the prevalence of P. falci-
parum parasitaemia by 88%. On the basis of economic
cost estimates, the cost per case of anaemia averted was
found to be US$ 29.84. The cost per case of P. falciparum
parasitaemia averted was US$ 5.36.
Sensitivity analysis
The variables used in the sensitivity analysis and the
effects on the overall costs and cost-effectiveness are
shown in Table 2. If the price of SP decreased by 50%, the
unit cost of treatment per child per year reduces from US$
1.88 to US$ 1.61. If the cost of SP doubled, the unit cost
increases to US$ 2.30. The corresponding figures for halv-
ing or doubling the price of AQ are US$ 1.55 and US$
2.54. A 10% change in the wastage rate of drugs is associ-
ated with a 2.3% change in the price of IPT: if drug wast-
age decreased to 0%, the estimated cost decreases from
US$ 1.88 to US$ 1.80 whereas at a wastage rate of 20%,
costs would increase to US$ 1.95. Varying the exchange
rate between the highest and the lowest rates reported for
2006 varies the price of IPT from US$ 1.88 to between
US$ 1.78 (a decrease of 5%) and US$ 2.13 (an increase of
13.4%). Changing the discount rate had a negligible effect
on the overall price of IPT. Increasing personnel costs by
20% increase overall costs to US$ 1.96.
The results of the sensitivity analysis on the estimates of
cost-effectiveness are also presented in Table 2. By chang-
ing costs, the cost per case of anaemia averted varied
between US$ 24.60–40.32. The cost per case of malaria
parasitaemia varied between US$ 4.20–7.24. Lower levels
in the effectiveness of IPT were associated with markedly
worst cost-effectiveness ratios (Table 2). Cost effectiveness
depended most on the background prevalence of anae-
mia: in settings where 30% of children are anaemic the
cost per case of anaemia averted is US$ 12.53 and where
prevalence of anaemia is 50%, the cost per case of anae-
mia averted is US$ 7.52.
Alternative IPT regimes
Because drug price is the primary cost driver, varying the
type of drug used will considerably alter the overall cost of
school-based delivery of IPT; effectiveness of alternative
regimes is unknown at present. The cheapest IPT drug
option would be to deliver SP alone: approximately US$
1.19 per child per year (delivered three times a year), 33%
cheaper than SP/AQ. Conversely delivering DP three
times a year would cost US$ 4.50 per child which would
be 139% more expensive than SP/AQ. For DP to be finan-
cially comparable to the current price of AQ/SP, its cost
per dose would have to fall from approximately US$ 1 per
treatment dose to US$ 0.20. Decreasing the frequency of
delivery from three times to twice a year would decrease
the cost of IPT from US$ 1.88 to US$ 1.42 (a 24%
decrease). The effectiveness of alternative drug regimes
and biannual treatment is unknown at present.
Discussion
Numerous studies have investigated the cost-effectiveness
of malaria control measures in Africa [21-25]. This study
provides, to our knowledge, the first estimates of the cost
and cost-effectiveness of a school-based malaria interven-
tion and suggests that IPT administered by teachers is a
potentially cost-effective school-based strategy, meriting
further investigation.
Differences in outcome measures, target population,
methodology and assumptions make it difficult to com-
pare our results with other community-based malaria
control interventions. Nonetheless, in terms of affordabil-
ity, the per capita cost of IPT through schools (US$ 1.88
per child treated per year) compares favourably with esti-
mated costs of other malaria interventions including
insecticide treated nets (ITNs) and indoor residual spray-
ing (IRS), which are considered 'attractive' low cost inter-
ventions for both low and middle income countries. ITNs
are estimated to cost between US$1.40 and 3.85 per per-
son protected per year [24] and IRS is estimated to cost
between US$0.88 and 3.48 per person protected per year
[26].
The costs of a school-based IPT programme are primarily
driven by drug price and cost of personnel which account
for 38.4% and 39.6% of the overall annual costs of treat-
ing a child, respectively. Any decrease in drug price over
time will therefore act to increase the future financial
attractiveness of IPT, 50% decrease in the price of AQ or
SP would show a decrease in the price of IPT from US$
1.88 to US$ 1.61 or US$ 1.55, respectively. The converse
is true of personnel costs which are expected to rise over
time and will decrease IPT's economic attractiveness: a
20% wage increase in Kenya would be associated with an
increase in IPT price from US$ 1.88 to US$ 1.96 per child
treated. This change in overall price is relatively low con-
sidering that personal costs are the largest cost driver and
demonstrates the robustness of the price of IPT to short
term changes in unit costs.M
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Table 2: Sensitivity analysis variables and outcomes
Variable Baseline 
value
Revised 
values  
in
sensitivity 
analysis
Justification Impact on  
cost per child
per year
(Baseline:
US$1.88)
Impact on Cost effectiveness
Cost per case of 
anaemia averted
(Baseline: US$ 29.84)
Cost per case of 
parasitaemia averted
(Baseline: US$ 5.36)
SP Price US$ 0.08 per dose 200% Drug price and brand are 
liable to change over time 
and across settings
US$ 1.61
US$ 2.30
US$ 25.56
US$ 36.51
US$ 4.59
US$ 6.55
AQ Price US$ 0.12 per dose 50%
200%
As above US$ 1.55
US$ 2.54
US$ 24.60
US$ 40.32
US$ 4.2
US$ 7.24
Drug Wastage 10% 0%
20%
Variations in expert 
opinion & literature
US$ 1.80
US$ 1.95
US$ 28.57
US$ 30.95
US$ 5.13
US$ 5.56
Exchange rate US$ 1= Kes 67.81 US$ 1 = Kes 74.5
US$ 1 = Kes 67.1
Rate over 2006, and 
highest and lowest 2006 
rates
US$ 1.78
US$ 2.13
US$ 28.25
US$ 33.81
US$ 5.07
US$ 6.07
Discount rate 5% 3% – 7% 5% is standard practice, 
with 3–7% used 
occasionally
Negligible change Negligible change Negligible change
Change in wages 2006 + 20% Salaries levels liable to 
change. 20% is a realistic 
change in next few years
US$ 1.96 US$ 31.11 US$ 5.58
Effectiveness: reduction in 
% anaemia
50% 10%
30%
Effectiveness may vary in 
different settings and when 
implemented outside of an 
efficacy trial
Not applicable US$ 149.21
US$ 49.74
Not applicable
Effectiveness: reduction in 
% parasitaemia
88% 40%
60%
As above Not applicable Not applicable US$ 11.84
US$ 7.89
Baseline % anaemia in 
Reduction in % 
parasitaemia
12.6% 30%
50%
Background nutritional 
levels vary between 
settings
Not applicable US$ 12.53
US$ 7.52
Not applicable
Frequency of delivery Three times a year Twice a year Yearly distribution as in 
efficacy trial versus 
seasonal distribution
US$ 1.42 Not applicable Not applicable
Drug Choice SP/AQ SP alone
DP
Current drug regime 
versus alternative drug 
regime currently under 
investigation
US$ 1.19.
US$ 4.50
Not applicable Not applicableMalaria Journal 2008, 7:196 http://www.malariajournal.com/content/7/1/196
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Set-up costs accounted for 13.2% of overall costs whilst
recurrent costs account for 86.8%, equivalent to annual
programme cost of US$ 1.63 per child treated per year. As
an IPT programme is rolled-out, less frequent training of
trainers would be required, further reducing personnel
costs. Moreover, the simultaneous delivery by teachers of
both IPT and deworming as part of an integrated school
health package will yield what economists call economies
of scope – the joint delivery of two health care interven-
tions will be cheaper than a separate delivery of the same
interventions – resulting in lower average delivery costs
[27]. These factors would serve to reduce per capital costs.
The costings presented here represent a maximal cost of
delivering IPT, as no cost-sharing with other treatment
programmes has been assumed in our estimates. The
incremental cost-effectiveness of school-based IPT could
therefore prove to be substantially lower than we have
estimated.
In terms of cost-effectiveness, previous estimates for
malaria control use a variety of outcome measures,
including cost per death averted or cost per disability
adjusted life year (DALY) averted. The DALY model of
malaria is based the number of deaths and the number of
years lived with disability from malaria episodes, severe
anaemia and neurological sequelae, as defined in the Glo-
bal Burden of Disease 2002 study [28]. The impact of IPT
on these outcomes was not assessed and therefore a more
intermediate health outcome of anaemia was selected
since this was relatively common in the population, was a
more epidemiologically relevant outcome in older chil-
dren, and was able to be assessed empirically. The choice
of anaemia also enables our results to be compared with
other school-based interventions, notably school-based
deworming. In Uganda, the cost effectiveness of school
based anthelmintic treatment (using albendazole and
praziquantel) ranged between US$ 1.70 and US$ 9.51 per
anaemia case averted in different districts [29]. Similarly,
a study in Tanzania reported the cost per case of anaemia
averted to be US$ 7.43 [30]. Whereas the costs of
anthelmintic drugs are very low (< $ 0.20 per child), anti-
malarial drugs are more expensive, partly explaining the
higher costs per anaemia case averted of school-based IPT
(US$ 29.84) compared to school-based deworming (US$
1.70–9.51). However, the cost of IPT per anaemia case
averted will inevitably vary with the prevalence of anae-
mia, and so cost-effectiveness is likely to be most favoura-
ble where need is greatest: the cost per case of anaemia
averted is US$ 12.53 in settings where prevalence of anae-
mia is 30% and US$ 7.52 where prevalence is 50%.
In addition to the health benefits of reducing anaemia in
the intervention trial, there were immediate cognitive
benefits [16]. Two tests were administed, both assessing
sustained attention, the ability to concentrate on a task for
an extended period of time. In the intervention group,
scores for sustained attention were higher compared to
the control group with an effect size of 0.18 in one test
and 0.48 in the other. Cognitive abilities predict subse-
quent wages either directly [31] or through the long-term
effects on increased educational attainment [32]. Through
these mechanisms there may therefore also be education-
related returns on the investment in IPT.
Affordability and cost-effectiveness are clearly important
determinants of the long-term sustainability of the
school-based IPT, but also crucial are feasibility and
acceptability to the teachers, parents, health-workers and
the wider community. Here, a key issue will be drug
choice. Drugs best suited to mass treatment programmes
should be cheap, easy to administer – preferably as a sin-
gle dose – and well-tolerated with minimal side-effects.
For intermittent preventive treatment of malaria, a long
half-life is also advantageous. In this regard, SP alone and
DP are both good candidates for school-based IPT that are
being investigated in an ongoing trial in Uganda,
although SP's future effectiveness may be limited by
increasing parasite resistance against this drug. Alternative
drug regimes will vary in price, dependant on both the
cost per dose and the number of required doses. The
present study showed that using SP alone would decrease
the cost of treatment from US$ 1.88 to US$ 1.19 per child
per year. Conversely, using DP would considerably
increase the price of IPT from US$1.88 to US$ 4.50 per
child per year. Although the effectiveness of these alterna-
tive IPT regimes has yet to be determined, it is apparent
that the drugs chosen should be cheap, efficacious and
simple to deliver in order to maximize the cost effective-
ness of an IPT programme. In the efficacy trial, IPT was
delivered three times per year. The current analysis shows
that delivering IPT twice a year in association with the two
main malaria peaks would decrease the price of IPT by
approximately 24% (from US$ 1.88 to US$ 1.42 for SP/
AQ).
A particular strength of this analysis is that costs are based
on relevant information from the efficacy trial as well as
the current structure of school deworming programmes,
using best available data on relevant costs. However, the
results are also subject to a number of assumptions
including the discount rate, the drug wastage rate and the
exchange rate. The sensitivity analysis showed, however,
that the overall cost of IPT is relatively robust to these
assumptions. In terms of extrapolation to other settings,
Bondo District is representative of areas of stable peren-
nial malaria transmission in East Africa. Similarly, the dis-
trict's educational infrastructure is typical of rural East
Africa. Factors which may vary in other settings include
varying distances between schools and population densi-
ties which may alter the cost of IPT due to changing logis-Malaria Journal 2008, 7:196 http://www.malariajournal.com/content/7/1/196
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tical needs. There may also be savings in terms of teacher
training as the programme is rolled-out.
The primary limitation of the current analysis is that effec-
tiveness is estimated from the efficacy trial where the
study team delivered treatment. Programmatic delivery of
IPT by teachers as part of a school health programme may,
however, result in lower levels of effectiveness, which will
in turn influence cost-effectiveness. The effectiveness of
IPT may also vary according to the intensity and seasonal-
ity of malaria transmission. Although this aspect was
explored through sensitivity analysis, in practice the effec-
tiveness of school-based IPT is still largely unknown. To
investigate some of these issues, parallel studies are cur-
rently planned in coastal Kenya and sahelian Senegal to
assess the external validity of the study findings and to
investigate further the long term educational gains of IPT
in school.
IPT is one of a number of possible malaria control strate-
gies which could be able to be delivered through schools
[12]. The use of ITN has been associated with a 46%
reduction in the prevalence of anaemia among Kenyan
schoolgirls, aged 12–13 years [33], but was less effective in
preventing anaemia among younger children. Another
study among children in boarding schools in Kenya found
that the use of bednets was associated with a decreased
incidence of malaria [34]. Previously, global ITN guide-
lines focused primarily on providing ITNs for use by chil-
dren under the age of 5 years and pregnant women.
However, it has been recently recognized that protecting
all community members yields enhanced health benefits
and social equity, and WHO now recommends that Long-
Lasting Insecticide Nets (LLINs) should be distributed
freely or should be highly subsidized and used by all com-
munity members, including schoolchildren [35].
Conclusion
The results of this analysis suggest that the per child cost
of IPT in schools fall within the range of the per capita
costs of other malaria control strategies. In terms of cost-
effectiveness, IPT delivered by teachers is estimated to be
less attractive in terms of per anaemia case averted than
school-based deworming programmes. However, the
cost-effectiveness of school-based IPT is likely to be high-
est where anaemia is widespread and need is, therefore,
greatest. Furthermore, the simultaneous delivery by teach-
ers of both IPT and deworming as part of an integrated
school health package will yield further cost savings, so-
called economies of scope. The relative effectiveness of
IPT and deworming is currently unknown because the
impact of IPT observed in the efficacy trial was on top of
any effect of deworming since all children in the efficacy
trial received anthelmintics. In addition to the efficacy of
the intervention, cost-effectiveness will be influenced by
the choice of drug and frequency of treatment. Further
investigation of the effectiveness of school-based IPT in
differing epidemiological and programmatic settings is
clearly warranted.
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